Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.58 |
| ▸ | NCK1 | P16333 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521431 | 0.86 | BACE1 (0.52) | BACE1NCK1PLAUNCF1NPC1 | |
| SCHEMBL31091801 | 0.85 | BACE1 (0.58) | BACE1NCK1PLAUNCF1CTSD | |
| SCHEMBL5679246 | 0.82 | BACE1 (0.51) | BACE1NCK1PLAUNCF1CTSD | |
| SCHEMBL3976029 | 0.81 | NPC1 (0.42) | BACE1NCK1PLAUNPC1SCN4A | |
| SCHEMBL21195656 | 0.78 | NPC1 (0.43) | BACE1NPC1SCN4ARAB9ASMN1; SMN2 | |
| SCHEMBL1102403 | 0.78 | CYP1A2 (0.59) | NPC1SCN4ARAB9ASMN1; SMN2 | |
| SCHEMBL10122186 | 0.78 | NPC1 (0.43) | NPC1SCN4ARAB9ASMN1; SMN2 | |
| SCHEMBL15341749 | 0.78 | BACE1 (0.48) | BACE1NCK1PLAUNCF1CTSD | |
| SCHEMBL889349 | 0.78 | NPC1 (0.43) | BACE1NCK1NPC1SCN4ARAB9A | |
| SCHEMBL12938118 | 0.77 | NPC1 (0.48) | NPC1SCN4ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620413-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-02-01 | — | — | EP | claimed |
| WO-2004098494-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-3690973-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIV SOUTHERN CALIFORNIA (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240324264-A1 | OLED WITH HYBRID EMISSIVE LAYER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-09-26 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12029055-B2 | OLED with hybrid emissive layer | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| US-12029055-B2 | OLED with hybrid emissive layer | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| US-12029055-B2 | OLED with hybrid emissive layer | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| US-11812624-B2 | Organic electroluminescent materials and devices | UNITED STATES DEPARTMENT OF ENERGY | 2023-11-07 | — | — | US | disclosed |
| US-11812624-B2 | Organic electroluminescent materials and devices | UNITED STATES DEPARTMENT OF ENERGY | 2023-11-07 | — | — | US | disclosed |
| US-11812624-B2 | Organic electroluminescent materials and devices | UNITED STATES DEPARTMENT OF ENERGY | 2023-11-07 | — | — | US | disclosed |
| US-9161924-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140219989-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-07 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| EP-1620413-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098494-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140219989-A1 | FACTOR IXA INHIBITORS | F9, F12, F11 | BACE1 1847/4885NCK1 4270/4885PLAU 43/4885 |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | BACE1 1918/4885NCK1 308/4885PLAU 2897/4885 |
| US-11812624-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, HCRTR2 | BACE1 1494/4885NCK1 1300/4885PLAU 3668/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | BACE1 3377/4885NCK1 4611/4885PLAU 57/4885 |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | BACE1 3454/4885NCK1 435/4885PLAU 3989/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | BACE1 942/4885NCK1 87/4885PLAU 2943/4885 |
| US-12029055-B2 | OLED with hybrid emissive layer | S1PR4, S1PR1, S1PR2 | BACE1 323/4885NCK1 2350/4885PLAU 3475/4885 |
| US-20240324264-A1 | OLED WITH HYBRID EMISSIVE LAYER | S1PR4, S1PR2, S1PR1 | BACE1 348/4885NCK1 2276/4885PLAU 3302/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | BACE1 1918/4885NCK1 308/4885PLAU 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.